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INTRODUCTION: This study protocol describes a trial designed to investigate
whether antihistamine alone in patients with acute urticaria does not increase the
7-day Urticaria Activity Score (UAS7) in comparison with an association of
antihistamine and glucocorticoids and reduces short-term relapses and chronic-
induced urticaria.
METHODS AND ANALYSIS: This is a prospective, double-blind, parallel-group,
multicentre non-inferiority randomised controlled trial. Two-hundred and forty
patients with acute urticaria admitted to emergency department will be randomised
in a 1:1 ratio to receive levocetirizine or an association of levocetirizine and
prednisone. Randomisation will be stratified by centre. The primary outcome will be
the UAS7 at day 7. The secondary outcomes will encompass recurrence of hives
and/or itch at day 7; occurrence of spontaneous hives or itch for >6 weeks; patients
with angioedema at day 7, and 2, 6, 12 and 24 weeks; new emergency visits for
acute urticaria recurrences at days 7 and 14, and 3 months; Dermatology Life
Quality Index at days 7 and 14, and 3 and 6 months; and Chronic Urticaria Quality
of Life Questionnaire at 6 weeks.
ETHICS AND DISSEMINATION: The protocol has been approved by the and will be
carried out in accordance with the Declaration of Helsinki and Good Clinical
Practice guidelines. A steering committee will oversee the progress of the study.
Findings will be disseminated through national and international scientific
conferences and publication in peer-reviewed journals.
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